Life Technologies Inks Deal with iPS Academia Japan | GenomeWeb

NEW YORK (GenomeWeb News) – Life Technologies today announced a worldwide, non-exclusive deal with iPS Academia Japan for its induced pluripotent stem cell patent portfolio.

The agreement grants Life Tech the rights to commercialize a range of products and services designed to create iPS cells and differentiate them into any cell type for drug discovery and pre-clinical research. Life Tech will also be able to provide iPS cell creation, differentiation, and screening services to the scientific community.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: system to track intron gains and losses, role of RUNX during mitosis, and more.

French officials release a report and move to strength safety measures for clinical trials, ScienceInsider reports.

Researchers find different molecular signatures in cancers from men as compared to those from women, the Wall Street Journal reports.

Researchers trace the deaths of a pair of newborn siblings to a mutation in their LIPT1 genes through whole-exome sequencing, Stat News reports.